Adjuvant and neoadjuvant treatment for pancreatic adenocarcinoma in 2006;Traitement adjuvant et néoadjuvant des adénocarcinomes pancréatiques en 2006

Bulletin du Cancer

Volumn 94, Issue 1, 2007, Pages 72-80

  Deberne, Mélanie ^a   Huguet, Florence ^a   Le Scodan, Romuald ^b   Hammel, Pascal ^c   Andre, Thierry ^a  

^a HÔPITAL TENON   (France)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^c BEAUJON HOSPITAL   (France)

Author keywords

Adjuvant treatment; Chemoradiation; Gemcitabine; Neoadjuvant treatment; Pancreatic adenocarcinoma

Indexed keywords

BEVACIZUMAB; CISPLATIN; DOXORUBICIN; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GEMCITABINE; MITOMYCIN C; PACLITAXEL;

ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; HUMAN; META ANALYSIS; MULTIPLE CYCLE TREATMENT; PANCREAS ADENOCARCINOMA; RANDOMIZED CONTROLLED TRIAL; REVIEW; SURGICAL TECHNIQUE; SYSTEMATIC REVIEW; TUMOR LOCALIZATION;

ADENOCARCINOMA; CHEMOTHERAPY, ADJUVANT; HUMANS; NEOADJUVANT THERAPY; PANCREATIC NEOPLASMS; RADIOTHERAPY, ADJUVANT;

EID: 33846937363     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2007.0177     Document Type: Review

References (62)

1. Hill C, Doyon F. [The frequency of cancer in France in year 2002, and trends since 1968]. Bull Cancer 2006 ; 93 : 7-11.
2. Gudjonsson B. Cancer of the pancreas. 50 years of surgery. Cancer 1987 ; 60 : 2284-303.
3. Andre T, Balosso J, Louvet C, Gligorov J, Callard P, de Gramont A, et al. [Adenocarcinoma of the pancreas. General characteristics]. Presse Med 1998 ; 27 : 533-6.
4. Tepper J, Nardi G, Sutt H. Carcinoma of the pancreas : review of MGH experience from 1963 to 1973. Analysis of surgical failure and implications for radiation therapy. Cancer 1976 ; 37 : 1519-24.
5. Kayahara M, Nagakawa T, Ueno K, Ohta T, Takeda T, Miyazaki I. An evaluation of radical resection for pancreatic cancer based on the mode of recurrence as determined by autopsy and diagnostic imaging. Cancer 1993 ; 72 : 2118-23.
6. Griffin JF, Smalley SR, Jewell W, Paradelo JC, Reymond RD, Hassanein RE, et al. Patterns of failure after curative resection of pancreatic carcinoma. Cancer 1990 ; 66 : 56-61.
7. Westerdahl J, Andren-Sandberg A, Ihse I. Recurrence of exocrine pancreatic cancer: local or hepatic? Hepatogastroenterology 1993 ; 40 : 384-7.
8. Yeo CJ, Abrams RA, Grochow LB, Sohn TA, Ord SE, Hruban RH, et al. Pancreaticoduodenectomy for pancreatic adenocarcinoma : postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience. Ann Surg 1997 ; 225 : 621-33 ; [discussion 633-6].
9. Whittington R, Bryer MP, Haller DG, Solin LJ, Rosato EF. Adjuvant therapy of resected adenocarcinoma of the pancreas. Int J Radiat Oncol Biol Phys 1991 ; 21 : 1137-43.
10. Mornex F, Girard N, Delpero JR, Partensky C. Radiochemotherapy in the management of pancreatic cancer: part I : neoadjuvant treatment. Semin Radiat Oncol 2005 ; 15 : 226-34.
11. Yeo CJ, Cameron JL, Sohn TA, Lillemoe KD, Pitt HA, Talamini MA, et al. Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s : pathology, complications, and outcomes. Ann Surg 1997 ; 226 : 248-57 ; [discussion 257-60].
12. Birkmeyer JD, Stukel TA, Siewers AE, Goodney PP, Wennberg DE, Lucas FL. Surgeon volume and operative mortality in the United States. N Engl J Med 2003 ; 349 : 2117-27.
13. McPhee JT, Zayaruzny M, Whalen GF, Litwin DE, Sullivan ME, Anderson FA, et al. Pancreatectomy for neoplasm : Current national trends in mortality and disposition. In : ASCO Gastrointestinal Cancers Symposium. 2006.
14. Harrison LE, Klimstra DS, Brennan MF. Isolated portal vein involvement in pancreatic adenocarcinoma. A contraindication for resection? Ann Surg 1996 ; 22 : 342-7 ; [discussion 347-9].
15. Leach SD, Lee JE, Charnsangavej C, Cleary KR, Lowy AM, Fenoglio CJ, et al. Survival following pancreaticoduodenectomy with resection of the superior mesenteric-portal vein confluence for adenocarcinoma of the pancreatic head. Br J Surg 1998 ; 85 : 611-7.
16. Fuhrman GM, Charnsangavej C, Abbruzzese JL, Cleary KR, Martin RG, Fenoglio CJ, et al. Thin-section contrast-enhanced computed tomography accurately predicts the resectability of malignant pancreatic neoplasms. Am J Surg 1994 ; 167 : 104-11 ; [discussion 111-3].
17. Yeo CJ, Cameron JL, Lillemoe KD, Sitzmann JV, Hruban RH, Goodman SN, et al. Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients. Ann Surg 1995 ; 221 : 721-31 ; [discussion 731-3].
18. Benassai G, Mastrorilli M, Quarto G, Cappiello A, Giani U, Forestieri P, et al. Factors influencing survival after resection for ductal adenocarcinoma of the head of the pancreas. J Surg Oncol 2000 ; 73 : 212-8.
19. Luttges J, Vogel I, Menke M, Henne-Bruns D, Kremer B, Kloppel G. The retroperitoneal resection margin and vessel involvement are important factors determining survival after pancreaticoduodenectomy for ductal adenocarcinoma of the head of the pancreas. Virchows Arch 1998 ; 433 : 237-42.
20. Millikan KW, Deziel DJ, Silverstein JC, Kanjo TM, Christein JD, Doolas A, et al. Prognostic factors associated with resectable adenocarcinoma of the head of the pancreas. Am Surg 1999 ; 65 : 618-23 ; [discussion 623-4].
21. Neoptolemos JP, Stocken DD, Dunn JA, Almond J, Beger HG, Pederzoli P, et al. Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Ann Surg 2001 ; 234 : 758-68.
22. Sohn TA, Yeo CJ, Cameron JL, Koniaris L, Kaushal S, Abrams RA, et al. Resected adenocarcinoma of the pancreas-616 patients : results, outcomes, and prognostic indicators. J Gastrointest Surg 2000 ; 4 : 567-79.
23. Wagner M, Redaelli C, Lietz M, Seiler CA, Friess H, Buchler MW. Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma. Br J Surg 2004 ; 91 : 586-94.
24. Willett CG, Lewandrowski K, Warshaw AL, Efird J, Compton CC. Resection margins in carcinoma of the head of the pancreas. Implications for radiation therapy. Ann Surg 1993 ; 217 : 144-8.
25. Pingpank Jr. JF, Hoffman JP, Sigurdson ER, Ross E, Sasson AR, Eisenberg BL. Pancreatic resection for locally advanced primary and metastatic nonpancreatic neoplasms. Am Surg 2002 ; 68 : 337-40 ; [discussion 340-1].
26. Ishikawa O, Ohigashi H, Sasaki Y, Kabuto T, Furukawa H, Nakamori S, et al. Practical grouping of positive lymph nodes in pancreatic head cancer treated by an extended pancreatectomy. Surgery 1997 ; 121 : 244-9.
27. Schwarz RE, Smith DD. Extent of lymph node staging for pancreatic cancer : information from a large US database. In : ASCO Gastrointestinal Cancers Symposium. 2005.
28. Bosset JF, Pavy JJ, Gillet M, Mantion G, Pelissier E, Schraub S. Conventional external irradiation alone as adjuvant treatment in resectable pancreatic cancer : results of a prospective study. Radiother Oncol 1992 ; 24 : 191-4.
29. Ducreux M, Boige V, Malka D. Chimiothérapie et radiothérapie. In : Levy P, Ruszniewski P, Sauvanet A, eds. Traité de pancréatologie. Paris : Flammarion, 2005.
30. Bakkevold KE, Arnesjo B, Dahl O, Kambestad B. Adjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas and papilla of Vater : results of a controlled, prospective, randomised multicentre study. Eur J Cancer 1993 ; 29A : 698-703.
31. Takada T, Amano H, Yasuda H, Nimura Y, Matsushiro T, Kato H, et al. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer 2002 ; 95 : 1685-95.
32. Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004 ; 350 : 1200-10.
33. Stocken DD, Buchler MW, Dervenis C, Bassi C, Jeekel H, Klinkenbijl JH, et al. Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer. Br J Cancer 2005 ; 92 : 1372-81.
34. Kalser MH, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985 ; 120 : 899-903.
35. Klinkenbijl JH, Jeekel J, Sahmoud T, van Pel R, Couvreur ML, Veenhof CH, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region : phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 1999 ; 230 : 776-82 ; [discussion 782-4].
36. Burris 3rd HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer : a randomized trial. J Clin Oncol 1997 ; 15 : 2403-13.
37. Neuhaus P, Oettle H, Post S, Gellert K, Ridwelski K, Schramm H, et al. A randomised, prospective, multicenter, phase III trial of adjuvant chemotherapy with gemcitabine vs. observation in patients with resected pancreatic cancer. J Clin Oncol 2005(suppl) : 23.
38. Mehta VK, Fisher GA, Ford JM, Oberhelman HA, Vierra MA, Bastidas AJ, et al. Adjuvant radiotherapy and concomitant 5-fluorouracil by protracted venous infusion for resected pancreatic cancer. Int J Radiat Oncol Biol Phys 2000 ; 48 : 1483-7.
39. Regine WF, Winter KW, Abrams R, Safran H, Hoffman JP, Konski A, et al. RTOG 9704 a phase III study of adjuvant pre and post chemoradiation (CRT) 5-FU vs. gemcitabine (G) for resected pancreatic adenocarcinoma. J Clin Oncol 2006(suppl) : 24.
40. Spitz FR, Abbruzzese JL, Lee JE, Pisters PW, Lowy AM, Fenoglio CJ, et al. Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas. J Clin Oncol 1997 ; 15 : 928-37.
41. Ishikawa O, Ohhigashi H, Teshima T, Chatani M, Inoue T, Tanaka S, et al. Clinical and histopathological appraisal of preoperative irradiation for adenocarcinoma of the pancreatoduodenal region. J Surg Oncol 1989 ; 40 : 143-51.
42. Partensky C, Maddern G. [Pancreatectomy after neoadjuvant chemoradiotherapy for potentially resectable exocrine adenocarcinoma of the pancreas]. Cancer Radiother 1998 ; 2 : 771-4.
43. Pilepich MV, Miller HH. Preoperative irradiation in carcinoma of the pancreas. Cancer 1980 ; 46 : 1945-9.
44. Turrini O, Moutardier V, Guiramand J, Lelong B, Bories E, Sannini A, et al. Hemorrhage after duodenopancreatectomy : impact of neoadjuvant radiochemotherapy and experience with sentinel bleeding. World J Surg 2005 ; 29: 212-6.
45. Ishikawa O, Ohigashi H, Imaoka S, Sasaki Y, Iwanaga T, Matayoshi Y, et al. Is the long-term survival rate improved by preoperative irradiation prior to Whipple's procedure for adenocarcinoma of the pancreatic head? Arch Surg 1994 ; 129 : 1075-80.
46. Evans DB, Rich TA, Byrd DR, Cleary KR, Connelly JH, Levin B, et al. Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg 1992 ; 127 : 1335-9.
47. Hoffman JP, Lipsitz S, Pisansky T, Weese JL, Solin L, Benson 3rd AB. Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized, resectable adenocarcinoma of the pancreas : an Eastern Cooperative Oncology.Group Study. J Clin Oncol 1998 ; 16 : 317-23.
48. White RR, Hurwitz HI, Morse MA, Lee C, Anscher MS, Paulson EK, et al. Neoadjuvant chemoradiation for localized adenocarcinoma of the pancreas. Ann Surg Oncol 2001 ; 8 : 758-65.
49. Pisters PW, Abbruzzese JL, Janjan NA, Cleary KR, Charnsangavej C, Goswitz MS, et al. Rapid-fractionation preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for resectable pancreatic adenocarcinoma. J Clin Oncol 1998 ; 16 : 3843-50.
50. Mornex F, Girard N, Scoazec JY, Bossard N, Ychou M, Smith D, et al. Feasibility of preoperative combined radiation therapy and chemotherapy with 5-fluorouracil and cisplatin in potentially resectable pancreatic adenocarcinoma : The French SFRO-FFCD 97-04 phase II trial. Int J Radiat Oncol Biol Phys 2006 ; 65 : 1471-8.
51. Wolff RA, Evans DB, Crane CH, Cleary KR, Lenzi R, Abbruzzese JL, et al. Initial results of preoperative gemcitabine (GEM)-based chemoradiation for resectable pancreatic adenocarcinoma. In : ASCO Annual Meeting. 2002.
52. Ammori JB, Colletti LM, Zalupski MM, Eckhauser FE, Greenson JK, Dimick J, et al. Surgical resection following radiation therapy with concurrent gemcitabine in patients with previously unresectable adenocarcinoma of the pancreas. J Gastrointest Surg 2003 ; 7 : 766-72.
53. Sa Cunha A, Rault A, Laurent C, Adhoute X, Vendrely V, Bellannee G, et al. Surgical resection after radiochemotherapy in patients with unresectable adenocarcinoma of the pancreas. J Am Coll Surg 2005 ; 201 : 359-65.
54. Rich T, Harris J, Abrams R, Erickson B, Doherty M, Paradelo J, et al. Phase II study of external irradiation and weekly paclitaxel for nonmetastatic, unresectable pancreatic cancer : RTOG-98-12. Am J Clin Oncol 2004 ; 27 : 51-6.
55. Pisters PW, Wolff RA, Janjan NA, Cleary KR, Charnsangavej C, Crane CN, et al. Preoperative paclitaxel and concurrent rapid-fractionation radiation for resectable pancreatic adenocarcinoma : toxicities, histologic response rates, and event-free outcome. J Clin Oncol 2002 ; 20 : 2537-44.
56. Krempien R, Muenter MW, Huber PE, Nill S, Friess H, Timke C, et al. Randomized phase II: study evaluating EGFR targeting therapy with cetuximab in combination with radiotherapy and chemotherapy for patients with locally advanced pancreatic cancer - PARC : study protocol. BMC Cancer 2005 ; 5 : 131 ; [ISRCTN56652283].
57. Kortmansky JS, O'Reilly EM, Minsky BD, Puleio SA, Winkelmann J, Kelsen DP, et al. A phase I trial of erlotinib, gemcitabine and radiation for patients with locally advanced, unresectable pancreatic cancer. J Clin Oncol 2005(suppl) : 23.
58. Iannitti D, Dipetrillo T, Akerman P, Barnett JM, Maia-Acuna C, Cruff D, et al. Erlotinib and chemoradiation followed by maintenance erlotinib for locally advanced pancreatic cancer : a phase I study. Am J Clin Oncol 2005 ; 28 : 570-5.
59. Czito BG, Willett CG, Bendell JC, Morse MA, Tyler DS, Fernando NH, et al. Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer : phase I trial results. J Clin Oncol 2006 ; 24 : 656-62.
60. Crane CH, Ellis LM, Abbruzzese JL, Amos C, Xiong HQ, Ho L, et al. Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer. J Clin Oncol 2006 ; 24 : 1145-51.
61. Gastrointestinal Tumor Study Group. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Cancer 1987 ; 59 : 2006-10.
62. Talamonti MS, Small W, Mulcahy MF, Wayne JD, Attaluri V, Colletti LM, et al. A multi-institutional phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma. Ann Surg Oncol 2006 ; 13 : 150-8.